Metabolic shares suspended
By Ruth Beran
Friday, 10 June, 2005
Friday, 10 June, 2005
Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.
Related News
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
